Table 3.
Results of final MMNL model
| Attributes | Beta | OR for choosing deprescribing | OR 95% CI | P-value |
|---|---|---|---|---|
| Deprescribing constant | −0.13 | – | – | 0.853 |
| 1. Risk of stroke: for each additional person (out of 100) having a stroke in the deprescribing alternative compared with the status quo | ||||
| Stroke_Carer | −0.34 | 0.71 | (0.58–0.88) | 0.002 |
| Stroke_Person living with dementia (PLWD) | −0.23 | 0.80 | (0.58–1.09) | 0.156 |
| Stroke_Geriatrician | −0.34 | 0.71 | (0.55–0.92) | 0.010 |
| Stroke_Non-Geriatrician | −0.47 | 0.62 | (0.45–0.86) | 0.004 |
| 2. Risk of myocardial infarction: for each additional person (out of 100) having a myocardial infarction in the deprescribing alternative compared with the status quo | ||||
| Myocardial Infarction_Carer | −0.17 | 0.84 | (0.73–0.98) | 0.028 |
| Myocardial Infarction_PLWD | −0.06 | 0.94 | (0.81–1.10) | 0.457 |
| Myocardial Infarction_Geriatrician | −0.05 | 0.95 | (0.80–1.14) | 0.578 |
| Myocardial Infarction_Non-Geriatrician | −0.21 | 0.81 | (0.69–0.95) | 0.011 |
| 3. Risk of significant increase in blood pressure (BP): for each additional person (out 100) having a significant increase in BP in the deprescribing alternative compared with the status quo | ||||
| Blood Pressure_Carer | 0.012 | 1.013 | (0.93–1.10) | 0.776 |
| Blood Pressure_PLWD | 0.001 | 1.001 | (0.91–1.11) | 0.992 |
| Blood Pressure_Clinician | 0.004 | 1.004 | (0.95–1.07) | 0.898 |
| 4. Risk of falls: for each additional person (out of 100) avoiding a fall in the deprescribing alternative compared with the status quo | ||||
| Falls_Carer | 0.04 | 1.04 | (0.98–1.11) | 0.180 |
| Falls_PLWD | −0.02 | 0.98 | (0.91–1.05) | 0.516 |
| Falls_Geriatrician | 0.18 | 1.20 | (1.11–1.29) | <0.001 |
| Falls_Non-Geriatrician | 0.15 | 1.16 | (1.07–1.25) | <0.001 |
| 5. Risk of noticeable decline in cognitive function: for each additional person (out of 100) avoiding noticeable decline in cognitive function in the deprescribing alternative compared with the status quo | ||||
| Cognitive Decline_Carer | 0.24 | 1.27 | (1.09–1.48) | 0.002 |
| Cognitive Decline_PLWD | 0.02 | 1.02 | (0.92–1.12) | 0.747 |
| Cognitive Decline_Geriatrician | 0.16 | 1.17 | (1.03–1.33) | 0.014 |
| Cognitive Decline_Non-Geriatrician | 0.01 | 1.01 | (0.89–1.15) | 0.890 |
| 6. Pill burden: for one less tablet per day in the deprescribing alternative compared with the status quo | ||||
| Pill Burden_Carer | −0.26 | 0.77 | (0.46–1.29) | 0.321 |
| Pill Burden_PLWD | 0.67 | 1.95 | (1.08–3.52) | 0.026 |
| Pill Burden_Clinician | −0.16 | 0.85 | (0.55–1.33) | 0.478 |
Model parameters and fit:
| ||||
Note: Bold indicates statistical significance at P < 0.05 or P < 0.01.
Beta = estimated coefficient from model.
N = number of observations.
K = number of parameters in the model.
For each unit change in risk of benefit or harm, the respondent is either more likely (OR > 1), or less likely (OR < 1) to choose the deprescribing option relative to continuing the antihypertensive medicines; OR = 1 = respondent is equally likely to choose the deprescribing option or continuing the antihypertensive medicines, and there is no association between a unit change in risk of benefit or harm and choosing either alternative.